THE US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals' Dupixent (dupilumab) to treat adults with moderate-to-severe eczema (atopic dermatitis).
Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable.
It is indicated for use with or without topical corticosteroids, and is administered as an injection.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Mar 17